Meeting
2012 ASCO Annual Meeting
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer.
Authors
Valentina Guarneri
Department of Oncology, Hematology and Respiratory Diseases, Modena University Hospital, Modena, Italy
Valentina Guarneri , Elena Barbieri , Federico Piacentini , Maria Vittoria Dieci , Claudia Omarini , Guido Ficarra , Stefania Raffaella Bettelli , Pier Franco Conte
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 631)
DOI
10.1200/jco.2012.30.15_suppl.631
Abstract #
631
Poster Bd #
13B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2019 ASCO Annual Meeting
NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).
First Author: Sandra M. Swain
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2018 ASCO Annual Meeting
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.
First Author: Sandra M. Swain